Literature DB >> 10694725

Case reports of olanzapine treatment of anorexia nervosa.

M C La Via1, N Gray, W H Kaye.   

Abstract

Two females with severe anorexia nervosa were treated with olanzapine in open trials. Olanzapine was tried because it has caused weight gain in other patient groups. Both anorexic patients had a chronic illness and had failed multiple other treatments. Olanzapine administration was associated with weight gain and maintenance as well as reduced agitation and resistance to treatment. These case histories support further exploration of this class of drugs in anorexia nervosa. Copyright 2000 by John Wiley & Sons, Inc.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10694725     DOI: 10.1002/(sici)1098-108x(200004)27:3<363::aid-eat16>3.0.co;2-5

Source DB:  PubMed          Journal:  Int J Eat Disord        ISSN: 0276-3478            Impact factor:   4.861


  8 in total

1.  Olanzapine use in adolescent anorexia nervosa.

Authors:  K Dennis; D Le Grange; J Bremer
Journal:  Eat Weight Disord       Date:  2006-06       Impact factor: 4.652

2.  Differential weight restoration on olanzapine versus fluoxetine in identical twins with anorexia nervosa.

Authors:  Vikas Duvvuri; Taya Cromley; Megan Klabunde; Kerri Boutelle; Walter H Kaye
Journal:  Int J Eat Disord       Date:  2011-02-22       Impact factor: 4.861

Review 3.  The psychopharmacotherapy of anorexia nervosa: clinical, neuroendocrine and metabolic aspects.

Authors:  G Abbate Daga; L Gianotti; V Mondelli; R Quartesan; S Fassino
Journal:  J Endocrinol Invest       Date:  2004-11       Impact factor: 4.256

4.  A double-blind, placebo-controlled study of risperidone for the treatment of adolescents and young adults with anorexia nervosa: a pilot study.

Authors:  Jennifer Hagman; Jane Gralla; Eric Sigel; Swan Ellert; Mindy Dodge; Rick Gardner; Teri O'Lonergan; Guido Frank; Marianne Z Wamboldt
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2011-08-05       Impact factor: 8.829

Review 5.  Canadian practice guidelines for the treatment of children and adolescents with eating disorders.

Authors:  Jennifer Couturier; Leanna Isserlin; Mark Norris; Wendy Spettigue; Melissa Brouwers; Melissa Kimber; Gail McVey; Cheryl Webb; Sheri Findlay; Neera Bhatnagar; Natasha Snelgrove; Amanda Ritsma; Wendy Preskow; Catherine Miller; Jennifer Coelho; Ahmed Boachie; Cathleen Steinegger; Rachel Loewen; Techiya Loewen; Elizabeth Waite; Catherine Ford; Kerry Bourret; Joanne Gusella; Josie Geller; Adele LaFrance; Anick LeClerc; Jennifer Scarborough; Seena Grewal; Monique Jericho; Gina Dimitropoulos; David Pilon
Journal:  J Eat Disord       Date:  2020-02-01

6.  Off-label indications for atypical antipsychotics: A systematic review.

Authors:  Konstantinos N Fountoulakis; Ioannis Nimatoudis; Apostolos Iacovides; George Kaprinis
Journal:  Ann Gen Hosp Psychiatry       Date:  2004-02-18

7.  Evaluation of the Effectiveness and Safety of Olanzapine as an Adjunctive Treatment for Anorexia Nervosa in Adolescents: An Open-Label Trial.

Authors:  Wendy Spettigue; Mark L Norris; Danijela Maras; Nicole Obeid; Stephen Feder; Megan E Harrison; Rebecca Gomez; Maeghan Cy Fu; Katherine Henderson; Annick Buchholz
Journal:  J Can Acad Child Adolesc Psychiatry       Date:  2018-07-01

8.  Evaluation of the efficacy and safety of olanzapine as an adjunctive treatment for anorexia nervosa in adolescent females: a randomized, double-blind, placebo-controlled trial.

Authors:  Wendy Spettigue; Annick Buchholz; Katherine Henderson; Stephen Feder; David Moher; Kader Kourad; Isabelle Gaboury; Mark Norris; Sheila Ledoux
Journal:  BMC Pediatr       Date:  2008-01-31       Impact factor: 2.125

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.